Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults
NCT05978908
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
24
Enrollment
OTHER
Sponsor class
Conditions
Safety Issues
Tolerance
Interventions
DRUG:
FC-12738
DRUG:
Saline
Sponsor
Neurodegenerative Disease Research Inc